» Articles » PMID: 19393012

Functional Significance of Brain Glycogen in Sustaining Glutamatergic Neurotransmission

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2009 Apr 28
PMID 19393012
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

The involvement of brain glycogen in sustaining neuronal activity has previously been demonstrated. However, to what extent energy derived from glycogen is consumed by astrocytes themselves or is transferred to the neurons in the form of lactate for oxidative metabolism to proceed is at present unclear. The significance of glycogen in fueling glutamate uptake into astrocytes was specifically addressed in cultured astrocytes. Moreover, the objective was to elucidate whether glycogen derived energy is important for maintaining glutamatergic neurotransmission, induced by repetitive exposure to NMDA in co-cultures of cerebellar neurons and astrocytes. In the astrocytes it was shown that uptake of the glutamate analogue D-[3H]aspartate was impaired when glycogen degradation was inhibited irrespective of the presence of glucose, signifying that energy derived from glycogen degradation is important for the astrocytic compartment. By inhibiting glycogen degradation in co-cultures it was evident that glycogen provides energy to sustain glutamatergic neurotransmission, i.e. release and uptake of glutamate. The relocation of glycogen derived lactate to the neuronal compartment was investigated by employing d-lactate, a competitive substrate for the monocarboxylate transporters. Neurotransmitter release was affected by the presence of d-lactate indicating that glycogen derived energy is important not only in the astrocytic but also in the neuronal compartment.

Citing Articles

Methionine Sulfoximine as a Tool for Studying Temporal Lobe Epilepsy: Initiator, Developer, Attenuator.

Albrecht J, Czuczwar S, Zielinska M, Miziak B Neurochem Res. 2025; 50(2):84.

PMID: 39843842 DOI: 10.1007/s11064-024-04329-z.


Neurological glycogen storage diseases and emerging therapeutics.

Colpaert M, Singh P, Donohue K, Pires N, Fuller D, Corti M Neurotherapeutics. 2024; 21(5):e00446.

PMID: 39277505 PMC: 11581880. DOI: 10.1016/j.neurot.2024.e00446.


The Effect of Inhibition of Perisynaptic Astrocyte Glycogen Utilization on Depression-Like Behavior.

Erk E, Demir B, Kursun H, Ozkan M, Dalkara T, Kocak E Turk Psikiyatri Derg. 2024; 34(4):272-281.

PMID: 38173328 PMC: 10786353. DOI: 10.5080/u27208.


Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.

Donohue K, Fitzsimmons B, Bruntz R, Markussen K, Young L, Clarke H Neurotherapeutics. 2023; 20(6):1808-1819.

PMID: 37700152 PMC: 10684475. DOI: 10.1007/s13311-023-01434-9.


Brain Mitochondrial Bioenergetics in Genetic Neurodevelopmental Disorders: Focus on Down, Rett and Fragile X Syndromes.

Valenti D, Vacca R Int J Mol Sci. 2023; 24(15).

PMID: 37569863 PMC: 10419900. DOI: 10.3390/ijms241512488.